← boothcheck

Is NHC overvalued?

boothcheck doesn't label NHC overvalued or undervalued, and it doesn't publish a fair value. It shows what the price assumes instead. At today's price, NHC is priced for growth of +13.5%, and an operating margin near 3.0% versus the 8.4% it earns today. The price is justified by relative-multiple and growth-DCF; asset-based/earnings-power land below the price. The more the price assumes beyond what NATIONAL HEALTHCARE CORP has actually delivered, the more has to go right to justify it. Whether that bar is too high is your call, and the full bull and bear cases are in the report.

Derived from NATIONAL HEALTHCARE CORP's SEC EDGAR filings via a reverse-DCF inversion. Last analyzed June 27, 2026.

Implied growth+13.5%
For about
Margin needed3.0%
Margin today8.4%
Price vs asset value2.24x
Price vs earnings power2.01x
Price vs peer multiples0.86x
Price vs forward growth0.83x
Read the full NHC report →
Get boothcheck's read on what NHC's price is betting on, in your inbox when it moves. No hype, no spam.
Free. Informational only, not investment advice. Unsubscribe anytime.

For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.